Related references
Note: Only part of the references are listed.Switch type I to type II TRK inhibitors for combating clinical resistance induced by xDFG mutation for cancer therapy
Shuang Xiang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2023)
Design, development and evaluation of a prodrug-type TrkA-selective inhibitor with antinociceptive effects in vivo
Siyuan Tang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2023)
Design, synthesis and biological evaluation of pyrazolo[3,4-b]pyridine derivatives as TRK inhibitors
Nian Liu et al.
RSC MEDICINAL CHEMISTRY (2023)
Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia
Eman M. E. Dokla et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2022)
Discovery of novel TrkA allosteric inhibitors: Structure-based virtual screening, biological evaluation and preliminary SAR studies
Jing Guo et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)
Rational drug design to explore the structure-activity relationship (SAR) of TRK inhibitors with 2,4-diaminopyrimidine scaffold
Tianxiao Wu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)
Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6H-pyrimido[5,4-b][1,4]oxazin-7(8H)-one Derivatives as A New Class of Potent Inhibitors of Pan-Trk and Their Drug-Resistant Mutants
Shulei Pan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Discovery of the First Highly Selective and Broadly EffectiveMacrocycle-Based Type II TRK Inhibitors that Overcome ClinicallyAcquired Resistance
Zuqin Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Discovery of quinazoline derivatives CZw-124 as a pan-TRK inhibitor with potent anticancer effects in vitro and in vivo
Tianxiao Wu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)
Conformational adjustment overcomes multiple drug-resistance mutants of tropomyosin receptor kinase
Long-Can Mei et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)
Design, synthesis and anti-tumor efficacy of novel phenyl thiazole/triazole derivatives as selective TrkA inhibitors
Xinyu Wang et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2022)
Identification and structural analysis of a selective tropomyosin receptor kinase C (TRKC) inhibitor
Zhijie Wang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)
Discovery of 3-pyrazolyl-substituted pyrazolo[1,5-a]pyrimidine derivatives as potent TRK inhibitors to overcome clinically acquired resistance
Yi Gong et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)
Discovery of CH7057288 as an Orally Bioavailable, Selective, and Potent pan-TRK Inhibitor
Toshiya Ito et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers
Tingting Jiang et al.
ACTA PHARMACEUTICA SINICA B (2021)
TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors
Emiliano Cocco et al.
CANCER DISCOVERY (2021)
Pyrazolo[1,5-a]pyrimidine based Trk inhibitors: Design, synthesis, biological activity evaluation
Yongjie Zhang et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2021)
Discovery of novel 2-phenylamino-4-prolylpyrimidine derivatives as TRK/ALK dual inhibitors with promising antitumor effects
Tong Li et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2021)
Design, synthesis and biological evaluation of macrocyclic derivatives as TRK inhibitors
Pei Li et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2021)
Transforming approaches to treating TRK fusion cancer: historical comparison of larotrectinib and histology-specific therapies
Megan Pollack et al.
CURRENT MEDICAL RESEARCH AND OPINION (2021)
Design and synthesis of novel orally selective and type II pan-TRK inhibitors to overcome mutations by property-driven optimization
Mu-Chun Li et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Design, synthesis, biological evaluation and pharmacophore model analysis of novel tetrahydropyrrolo[3,4-c]pyrazol derivatives as potential TRKs inhibitors
Tianxiao Wu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Discovery of Next-Generation Tropomyosin Receptor Kinase Inhibitors for Combating Multiple Resistance Associated with Protein Mutation
Lin-Sheng Zhuo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations
Brion W. Murray et al.
MOLECULAR CANCER THERAPEUTICS (2021)
In Pursuit of an Allosteric Human Tropomyosin Kinase A (hTrkA) Inhibitor for Chronic Pain
Govindan Subramanian et al.
ACS MEDICINAL CHEMISTRY LETTERS (2021)
Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion Cancer
Theodore W. Laetsch et al.
CLINICAL CANCER RESEARCH (2021)
Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation
Wei Yan et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
An update of new small-molecule anticancer drugs approved from 2015 to 2020
Xiaoxia Liang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Discovery of the Next-Generation Pan-TRK Kinase Inhibitors for the Treatment of Cancer
Zongliang Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Tropomyosin receptor kinase inhibitors: an updated patent review for 2016-2019
Justin J. Bailey et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2020)
Characterization of on-target adverse events caused by TRK inhibitor therapy
D. Liu et al.
ANNALS OF ONCOLOGY (2020)
TRK fusion positive cancers: From first clinical data of a TRK inhibitor to future directions
Giandomenico Roviello et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2020)
Design, synthesis, and Structure-Activity Relationships (SAR) of 3-vinylindazole derivatives as new selective tropomyosin receptor kinases (Trk) inhibitors
Yunxin Duan et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Discovery of First-In-Class Potent and Selective Tropomyosin Receptor Kinase Degraders
Liqun Chen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Design, synthesis and biological activity of bicyclic carboxamide derivatives as TRK inhibitors
Minghao Sun et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2020)
Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants
Beilei Wang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Selectively Targeting Tropomyosin Receptor Kinase A (TRKA) via PROTACs
Weiguo Xiang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors
Romel Somwar et al.
COMMUNICATIONS BIOLOGY (2020)
Discovery of Allosteric, Potent, Subtype Selective, and Peripherally Restricted TrkA Kinase Inhibitors
Sharan K. Bagal et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application
Wei Yan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor efficacy in AML cell inoculated mouse xenograft model
Hao Heng et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Targeting tropomyosin receptor kinase for cancer therapy
Qi Miao et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer
Noah Federman et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2019)
Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study
Theodore W. Laetsch et al.
LANCET ONCOLOGY (2018)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
A. Drilon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Inhibiting TRK Proteins in Clinical Cancer Therapy
Allison M. Lange et al.
CANCERS (2018)
Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibit ROS1/TRK/ALK Solvent-Front Mutations
Alexander Drilon et al.
CANCER DISCOVERY (2018)
Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia
Xuesong Liu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
NTRK fusion-positive cancers and TRK inhibitor therapy
Emiliano Cocco et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Structural characterization of nonactive site, TrkA-selective kinase inhibitors
Hua-Poo Su et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors
Alexander Drilon et al.
CANCER DISCOVERY (2017)
Fast-TRKing Drug Development for Rare Molecular Targets
Aparna R. Parikh et al.
CANCER DISCOVERY (2017)
The juxtamembrane region of TrkA kinase is critical for inhibitor selectivity
Noritaka Furuya et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
Blocking the tropomyosin receptor kinase A (TrkA) receptor inhibits pain behaviour in two rat models of osteoarthritis
Lilian N. Nwosu et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer
Mariangela Russo et al.
CANCER DISCOVERY (2016)
NGF/TrkA Signaling as a Therapeutic Target for Pain
Munetaka Hirose et al.
PAIN PRACTICE (2016)
What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)
A. Drilon et al.
ANNALS OF ONCOLOGY (2016)
TPX-0005, a novel ALK/ROS1/TRK inhibitor, effectively inhibited a broad spectrum of mutations including solvent front ALK G1202R, ROS1 G2032R and TRKA G595R mutants
J. J. Cui et al.
EUROPEAN JOURNAL OF CANCER (2016)
Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor
Maria Menichincheri et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
Elena Ardini et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Neurotrophic factor control of satiety and body weight
Baoji Xu et al.
NATURE REVIEWS NEUROSCIENCE (2016)
Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation
Yung Chang Hsu et al.
ONCOTARGET (2016)
Selective inhibition of tropomyosin-receptor-kinase A (TrkA) reduces pain and joint damage in two rat models of inflammatory arthritis
Sadaf Ashraf et al.
ARTHRITIS RESEARCH & THERAPY (2016)
NTRK gene fusions as novel targets of cancer therapy across multiple tumour types
Alessio Amatu et al.
ESMO OPEN (2016)
Chromosomal rearrangements involving the NTRK1 gene in colorectal carcinoma
Laurent Creancier et al.
CANCER LETTERS (2015)
An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101
Robert C. Doebele et al.
CANCER DISCOVERY (2015)
TRKing Down an Old Oncogene in a New Era of Targeted Therapy
Aria Vaishnavi et al.
CANCER DISCOVERY (2015)
Maximizing Diversity from a Kinase Screen: Identification of Novel and Selective pan-Trk Inhibitors for Chronic Pain
Shawn J. Stachel et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition
Elena Ardini et al.
MOLECULAR ONCOLOGY (2014)
Secretory breast carcinoma: A report of three cases and a review of the literature
Seung Geun Lee et al.
ONCOLOGY LETTERS (2014)
Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer
Aria Vaishnavi et al.
NATURE MEDICINE (2013)
The Crystal Structures of TrkA and TrkB Suggest Key Regions for Achieving Selective Inhibition
T. Bertrand et al.
JOURNAL OF MOLECULAR BIOLOGY (2012)
Characterization of a newly identified ETV6-NTRK3 fusion transcript in acute myeloid leukemia
Johanna M. Kralik et al.
DIAGNOSTIC PATHOLOGY (2011)
Functional Characterization of Human Cancer-Derived TRKB Mutations
Thomas R. Geiger et al.
PLOS ONE (2011)
Rearrangements of NTRK1 gene in papillary thyroid carcinoma
A. Greco et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2010)
Brain-Derived Neurotrophic Factor (BDNF) has Proliferative Effects on Neural Stem Cells through the Truncated TRK-B Receptor, MAP Kinase, AKT, and STAT-3 Signaling Pathways
Omedul Islam et al.
CURRENT NEUROVASCULAR RESEARCH (2009)
TrkA overexpression enhances growth and metastasis of breast cancer cells
C. Lagadec et al.
ONCOGENE (2009)
Discontinued drugs in 2007: oncology drugs
Robert Williams
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of Trk kinases
Tao Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Appetite Enhancement and Weight Gain by Peripheral Administration of TrkB Agonists in Non-Human Primates
John C. Lin et al.
PLOS ONE (2008)
Trk signaling regulates neural precursor cell proliferation and differentiation during cortical development
Katarzyna Bartkowska et al.
DEVELOPMENT (2007)
ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and sortilin
HK Teng et al.
JOURNAL OF NEUROSCIENCE (2005)
A chemoattractant role for NT-3 in proprioceptive axon guidance
B Genç et al.
PLOS BIOLOGY (2004)
A de novo mutation affecting human TrkB associated with severe obesity and developmental delay
GSH Yeo et al.
NATURE NEUROSCIENCE (2004)
The signaling adapters fibroblast growth factor receptor substrate 2 and 3 are activated by the thyroid TRK oncoproteins
V Ranzi et al.
ENDOCRINOLOGY (2003)
Biological activity of the thyroid TRK-T3 oncogene requires signalling through Shc
E Roccato et al.
BRITISH JOURNAL OF CANCER (2002)
Trk receptor tyrosine kinases: A bridge between cancer and neural development
A Nakagawara
CANCER LETTERS (2001)
Molecular basis of congenital insensitivity to pain with anhidrosis (CIPA): Mutations and polymorphisms in TRKA (NTRK1) gene encoding the receptor tyrosine kinase for nerve growth factor
Y Indo
HUMAN MUTATION (2001)
Neurotrophins: Roles in neuronal development and function
EJ Huang et al.
ANNUAL REVIEW OF NEUROSCIENCE (2001)
Identification and characterization of an activating TrkA deletion mutation in acute myeloid leukemia
GW Reuther et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
Share Paper
